Skip to main content
TrimSoMoEverything GLP-1, in one place
Program Profile

LillyDirect

Is LillyDirect listed in FDA warning letters?

No FDA warning letters addressed to LillyDirect appear in our dataset (FDA.gov letters 2023–2026). FDA has issued 3 warning letters to the manufacturer, Eli Lilly and Company: 2025-09-09, 2025-09-09, 2025-09-09. Subject named in the FDA records: "False & Misleading Claims/Misbranded".

Key facts

  • •Care model: Manufacturer self-pay and access program.
  • •Medications discussed: Zepbound (tirzepatide), Foundayo (orforglipron).
  • •State availability: Confirm directly with program. Note: The reviewed program page did not provide a state availability list. Confirm pharmacy access directly.

Manufacturer self-pay program for Zepbound. A valid prescription is required; prescriber services are not represented as included.

At a glance
Care model
Manufacturer self-pay program
Medications discussed
Zepbound (tirzepatide), Foundayo (orforglipron)
Availability
Confirm with program
The reviewed program page did not provide a state availability list. Confirm pharmacy access directly.

FDA Warning Letter Records Identified

LillyDirect is the direct-to-consumer pharmacy and clinical fulfillment portal operated by manufacturer Eli Lilly and Company. Official FDA warning letters issued to the parent manufacturer concerning direct-to-consumer promotional video communications are detailed below.

Eli Lilly and Company

Center for Drug Evaluation and Research (CDER)

Issued: 2025-09-09

Subject: False & Misleading Claims/Misbranded

false or misleading promotional communication (misbranding)omission and minimization of serious risks and boxed warningfailure to submit promotional materials at time of initial dissemination

FDA says a direct-to-consumer video was false or misleading because it omitted and minimized serious risks of Zepbound and Mounjaro, including the boxed warning and contraindications, and that the video was not submitted to FDA on Form FDA-2253 at initial dissemination.

Eli Lilly and Company

Center for Drug Evaluation and Research (CDER)

Issued: 2025-09-09

Subject: False & Misleading Claims/Misbranded

False or misleading risk presentationOmission of material factsFailure to submit under Form FDA-2253

FDA says a promotional video for Zepbound omitted all risk information and limitations of use, creating a misleading impression of the drug's safety and approved use, and that the video was not submitted to FDA on Form FDA-2253 at initial publication.

Eli Lilly and Company

Center for Drug Evaluation and Research (CDER)

Issued: 2025-09-09

Subject: False & Misleading Claims/Misbranded

false or misleading promotional communication (misbranding)omission of risk informationomission of material facts (limitations of use)failure to submit under Form FDA-2253 at time of initial publication

FDA says a sponsored online video promoting Zepbound omitted all risk information and the drug's limitations of use, creating a misleading impression of safety and approved use, and was not submitted to FDA under Form FDA-2253 when initially published.

Questions to ask the program

Before you use this program

This is a manufacturer self-pay program for filling a prescription, not a care program. Read its terms on its own website.

  • •Is a prescription from your own clinician required?
  • •Which pharmacy fills the prescription, and how is it delivered?
  • •Who do you contact with questions about an order?
Sources

Source records

Lilly Zepbound website

Last checked Nov 4, 2026

Open original source

LillyDirect Foundayo product page

Last checked Nov 7, 2026

Open original source
Pre-Enrollment Verification

Evaluate Eligibility & Coverage Before Enrolling in LillyDirect

Check manufacturer copay card rules, federal program exclusions, and cash-pay vial terms for LillyDirect.

All Decision Tools
Financial Modeling

Copay & Savings Card Rules

Model out-of-pocket copays for Zepbound and Wegovy under commercial plans ($25/mo caps) vs. self-pay cash channels.

Clinical Prep

Baseline Lab & Safety Screen

Legitimate telehealth prescribers require baseline kidney and A1c bloodwork. Review required panels and boxed warnings before your intake.

Indication Check

FDA BMI Indication Gauge

Verify whether your BMI meets official FDA prescribing standards (BMI ≥30 or ≥27 with comorbidity) before paying non-refundable fees.

100% Client-Side Privacy: No personal health data is shared with providers or third parties.Independent consumer guidance based on official DailyMed FDA prescribing archives.
Patient Guidance & Safety

Telehealth Navigation & Checklist

Evaluating a digital clinic? Review our clinical checklists for verifying state licensure, required blood work, and navigating insurance coverage.

Notice outdated or missing information? Submit a source-linked correction request.